TABLE 1.
Demographic, phenotypic and treatment characteristics of each group based on the type of molecular analysis.
| rAMD (R) | nAMD (N) | Control (C) | |
|---|---|---|---|
| N patients | 17 | 17 | 16 |
| Mean age (SD) | 81.6 (±6.5) | 81.6 (±5.9) | 70.44 ± 2.47 |
| Females (%) | 13 (76.5%) | 13 (76.5%) | 8/8 |
| N eyes | 18 | 19 | 16 |
| Right eyes/left eyes | 14/4 | 7/13 | 10/6 |
| Neovascularization type: 1/2/3 | 15/2/1 | 16/3/1 | — |
| Presence of reticular pseudodrusen (%) | 5 (28%) | 7 (35%) | — |
| Presence of fibrosis (%) | 3 (17%) | 4 (20%) | — |
| Presence of cRORA | 4 (22%) | 10 (50%) | — |
| Presence of iRORA | 6 (33%) | 14 (70%) | — |
| Recurrences including IRF (%) | 9 (50%) | 17 (85%) | — |
| Recurrences including SRF (%) | 12 (67%) | 8 (40%) | — |
| Mean CRT in micrometers (SD) | 323 (±83) | 286 (±76) | — |
| Mean subfoveal choroidal thickness in micrometers (SD) | 150 (±121) | 166 (±64) | — |
| Treatment duration in months ± SD | 69.7 ± 35.1 | 55.4 ± 36.2 | — |
| Number of injections received ± SD | 59.6 ± 29.9 | 36.4 ± 26.7 | — |
| Weeks from preceding injection ± SEM | 5.89 ± 0.94 | 3.97 ± 0.29 | — |
| Anti-VEGF agent used (ranib./Aflib.) | 8/10 | 8/12 | — |
| Number of switches performed | |||
| 0 | 3 | 13 | — |
| 1 | 9 | 7 | — |
| 2 | 6 | 0 | — |
| Mean visual acuity at treatment initiation in ETDRS letters ± SD | 61.7 ± 12.5 | 63.1 ± 16.1 | — |
| Mean visual acuity change from baseline in ETDRS letters ± SD | 7.9 ± 12.5 | Before cataract surgery −9.4 ± 12.9 after cataract surgery 12.8 ± 11.8 | — |
cRORA, complete retinal pigment epithelium pigment and outer retinal atrophy; iRORA, incomplete retinal pigment epithelium pigment and outer retinal atrophy.